{"pmid":32480250,"title":"Protective effects of vaccinations and endemic infections on COVID-19: A hypothesis.","text":["Protective effects of vaccinations and endemic infections on COVID-19: A hypothesis.","Med Hypotheses","Meenakshisundaram, Ramachandran","Senthilkumaran, Subramanian","Thirumalaikolundusubramanian, Ponniah","32480250"],"journal":"Med Hypotheses","authors":["Meenakshisundaram, Ramachandran","Senthilkumaran, Subramanian","Thirumalaikolundusubramanian, Ponniah"],"date":"2020-06-02T11:00:00Z","year":2020,"_id":"32480250","source":"PubMed","week":"202023|Jun 01 - Jun 07","doi":"10.1016/j.mehy.2020.109849","keywords":["bcg","coronavirus","covid-19","measles","sars","vaccines"],"topics":["Treatment"],"weight":1,"_version_":1668437834947624960,"score":9.490897,"similar":[{"pmid":32344056,"pmcid":"PMC7194727","title":"Eosinophil Responses During COVID-19 Infections and Coronavirus Vaccination.","text":["Eosinophil Responses During COVID-19 Infections and Coronavirus Vaccination.","Eosinophils are circulating and tissue-resident leukocytes that have potent pro-inflammatory effects in a number of diseases. Recently, eosinophils have been shown to have a variety of other functions, including immunoregulation and antiviral activity. Eosinophil levels vary dramatically in a number of clinical settings, especially following eosinophil-targeted therapy, which is now available to selectively deplete these cells. There are key COVID-19-related questions concerning eosinophils whose answers affect recommended prevention and care. First, do patients with eosinophilia-associated diseases have an altered course of COVID-19? Second, do patients with eosinopenia (now intentionally induced by biological drugs) have unique COVID-19 susceptibility and/or disease course? This is a particularly relevant question as eosinopenia is associated with acute respiratory deterioration during infection with the Severe Acute Respiratory Syndrome (SARS)-Corona Virus (CoV)-2, the causative agent of COVID-19. Third, do eosinophils contribute to the lung pathology induced during COVID-19 and will they contribute to immunopotentiation potentially associated with emerging COVID-19 vaccines? Herein, we address these timely questions and project considerations during the emerging COVID-19 pandemic.","J Allergy Clin Immunol","Lindsley, Andrew W","Schwartz, Justin T","Rothenberg, Marc E","32344056"],"abstract":["Eosinophils are circulating and tissue-resident leukocytes that have potent pro-inflammatory effects in a number of diseases. Recently, eosinophils have been shown to have a variety of other functions, including immunoregulation and antiviral activity. Eosinophil levels vary dramatically in a number of clinical settings, especially following eosinophil-targeted therapy, which is now available to selectively deplete these cells. There are key COVID-19-related questions concerning eosinophils whose answers affect recommended prevention and care. First, do patients with eosinophilia-associated diseases have an altered course of COVID-19? Second, do patients with eosinopenia (now intentionally induced by biological drugs) have unique COVID-19 susceptibility and/or disease course? This is a particularly relevant question as eosinopenia is associated with acute respiratory deterioration during infection with the Severe Acute Respiratory Syndrome (SARS)-Corona Virus (CoV)-2, the causative agent of COVID-19. Third, do eosinophils contribute to the lung pathology induced during COVID-19 and will they contribute to immunopotentiation potentially associated with emerging COVID-19 vaccines? Herein, we address these timely questions and project considerations during the emerging COVID-19 pandemic."],"journal":"J Allergy Clin Immunol","authors":["Lindsley, Andrew W","Schwartz, Justin T","Rothenberg, Marc E"],"date":"2020-04-29T11:00:00Z","year":2020,"_id":"32344056","source":"PubMed","week":"202018|Apr 27 - May 03","doi":"10.1016/j.jaci.2020.04.021","keywords":["covid-19","coronavirus","eosinophils","hyperimmune","immunopathology","immunopotentiation","sars","vaccines"],"topics":["Mechanism","Treatment"],"weight":1,"_version_":1666138495829147651,"score":72.17219},{"pmid":32379923,"title":"Is BCG vaccination causally related to reduced COVID-19 mortality?","text":["Is BCG vaccination causally related to reduced COVID-19 mortality?","The ongoing severe acute respiratory sickness coronavirus 2 (SARS-CoV-2) pandemic has resulted in more than 3,600,000 detected cases of COVID-19 illness and nearly 260,000 deaths worldwide as of May 6, 2020. Recently, BCG vaccination was shown to correlate with reduced COVID-19 case fatality rates (Miller et al, 2020; Sala & Miyagawa, 2020; https://www.jsatonotes.com/2020/03/if-i-were-north-americaneuropeanaustral.html). The most recent data from publicly available resources also indicate that both COVID-19 incidence and total deaths are strongly associated with the presence or absence of national mandatory BCG vaccination programs. As seen in Table 1, seven of eight countries with very low numbers of total deaths (<40 per one million population) adopted a mandatory BCG vaccination program using one of a set of 6 separate BCG strains (Table 1). In contrast, COVID-19 mortality was markedly higher in countries where BCG vaccination is not widely administered or is given only to high-risk groups. COVID-19 mortality was also higher in countries where widespread BCG vaccination was discontinued more than 20 years ago and in countries that used the BCG Denmark strain regularly or temporarily. This raises the question of whether BCG vaccination and reduced COVID-19 mortality are causally related. An additional question is why different BCG strains may be variably associated with mortality.","EMBO Mol Med","Miyasaka, Masayuki","32379923"],"abstract":["The ongoing severe acute respiratory sickness coronavirus 2 (SARS-CoV-2) pandemic has resulted in more than 3,600,000 detected cases of COVID-19 illness and nearly 260,000 deaths worldwide as of May 6, 2020. Recently, BCG vaccination was shown to correlate with reduced COVID-19 case fatality rates (Miller et al, 2020; Sala & Miyagawa, 2020; https://www.jsatonotes.com/2020/03/if-i-were-north-americaneuropeanaustral.html). The most recent data from publicly available resources also indicate that both COVID-19 incidence and total deaths are strongly associated with the presence or absence of national mandatory BCG vaccination programs. As seen in Table 1, seven of eight countries with very low numbers of total deaths (<40 per one million population) adopted a mandatory BCG vaccination program using one of a set of 6 separate BCG strains (Table 1). In contrast, COVID-19 mortality was markedly higher in countries where BCG vaccination is not widely administered or is given only to high-risk groups. COVID-19 mortality was also higher in countries where widespread BCG vaccination was discontinued more than 20 years ago and in countries that used the BCG Denmark strain regularly or temporarily. This raises the question of whether BCG vaccination and reduced COVID-19 mortality are causally related. An additional question is why different BCG strains may be variably associated with mortality."],"journal":"EMBO Mol Med","authors":["Miyasaka, Masayuki"],"date":"2020-05-08T11:00:00Z","year":2020,"_id":"32379923","source":"PubMed","week":"202019|May 04 - May 10","doi":"10.15252/emmm.202012661","keywords":["bcg","covid-19","sars-cov-2","trained immunity","vaccination"],"topics":["Treatment"],"weight":1,"_version_":1666597097447620608,"score":65.32628},{"pmid":32422144,"title":"Perforin and resistance to SARS coronavirus 2.","text":["Perforin and resistance to SARS coronavirus 2.","J Allergy Clin Immunol","Cunningham, Louise","Simmonds, Peter","Kimber, Ian","Basketter, David Arthur","McFadden, John Paul","32422144"],"journal":"J Allergy Clin Immunol","authors":["Cunningham, Louise","Simmonds, Peter","Kimber, Ian","Basketter, David Arthur","McFadden, John Paul"],"date":"2020-05-19T11:00:00Z","year":2020,"_id":"32422144","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1016/j.jaci.2020.05.007","keywords":["bcg","covid","hlh","mas","sars","sars-cov-2","coronavirus","cytokine release","cytokine storm","cytotoxic t lymphocyte","metformin","natural killer","perforin","perforinopathy"],"topics":["Mechanism"],"weight":1,"_version_":1667159284546273280,"score":65.31271},{"pmid":32491976,"title":"School Nurses on the Front Lines of Healthcare: Infectious Diseases Popularized in the News.","text":["School Nurses on the Front Lines of Healthcare: Infectious Diseases Popularized in the News.","School nurses may deal with students presenting with symptoms associated with infections popularized in the news. Although rare, the implications of missing or misdiagnosing these infections are potentially life-threatening and devastating. We present three students presenting with febrile illnesses associated with neurologic symptoms, a rash, and fatigue, focusing on the initial assessment and management of these students and their associated \"hot topic\" infection. The authors also discuss two public health organizations, Centers for Disease Control and Prevention (https://www.cdc.gov/) and the World Health Organization (https://www.who.int/), online references for the school nurse to research both emerging and common infectious diseases.","NASN Sch Nurse","McNickle, Lauren","Olympia, Robert P","32491976"],"abstract":["School nurses may deal with students presenting with symptoms associated with infections popularized in the news. Although rare, the implications of missing or misdiagnosing these infections are potentially life-threatening and devastating. We present three students presenting with febrile illnesses associated with neurologic symptoms, a rash, and fatigue, focusing on the initial assessment and management of these students and their associated \"hot topic\" infection. The authors also discuss two public health organizations, Centers for Disease Control and Prevention (https://www.cdc.gov/) and the World Health Organization (https://www.who.int/), online references for the school nurse to research both emerging and common infectious diseases."],"journal":"NASN Sch Nurse","authors":["McNickle, Lauren","Olympia, Robert P"],"date":"2020-06-04T11:00:00Z","year":2020,"_id":"32491976","source":"PubMed","week":"202023|Jun 01 - Jun 07","doi":"10.1177/1942602X20921426","keywords":["acute flaccid myelitis","coronavirus infection","measles"],"topics":["Prevention"],"weight":1,"_version_":1668623433750020096,"score":54.04059},{"pmid":32417996,"title":"BCG versus COVID-19: impact on urology.","text":["BCG versus COVID-19: impact on urology.","PURPOSE: To search for evidence base for using BCG in the fight against COVID-19 and the possible impact of these clinical trials on urology practice. METHODS: A literature review about the basis of the ongoing clinical trials using BCG against COVID-19, as well as the use of BCG in urology and if there are any implications of these trials on our practice. RESULTS: Based on data from some epidemiological studies, there are some current clinical trials on the use BCG as a possible prophylactic vaccine against SARS CoV-2 which can affect urology practice. Urologists are already struggling with the global shortage of BCG which can be even more aggravated by such trials. In addition, if the ongoing trials proved the efficacy of BCG as a prophylaxis against COVID-19, this may open the door to more urological research opportunities to question the possibility that intra-vesical BCG, given its systemic immunologic effect, may have been protective to this subgroup of urological patients. CONCLUSION: The ongoing clinical trials using BCG against COVID-19 can affect our urology practice. We need to stay vigilant to such impacts: BCG shortage and possible new chances for urology research work.","World J Urol","Desouky, Elsayed","32417996"],"abstract":["PURPOSE: To search for evidence base for using BCG in the fight against COVID-19 and the possible impact of these clinical trials on urology practice. METHODS: A literature review about the basis of the ongoing clinical trials using BCG against COVID-19, as well as the use of BCG in urology and if there are any implications of these trials on our practice. RESULTS: Based on data from some epidemiological studies, there are some current clinical trials on the use BCG as a possible prophylactic vaccine against SARS CoV-2 which can affect urology practice. Urologists are already struggling with the global shortage of BCG which can be even more aggravated by such trials. In addition, if the ongoing trials proved the efficacy of BCG as a prophylaxis against COVID-19, this may open the door to more urological research opportunities to question the possibility that intra-vesical BCG, given its systemic immunologic effect, may have been protective to this subgroup of urological patients. CONCLUSION: The ongoing clinical trials using BCG against COVID-19 can affect our urology practice. We need to stay vigilant to such impacts: BCG shortage and possible new chances for urology research work."],"journal":"World J Urol","authors":["Desouky, Elsayed"],"date":"2020-05-18T11:00:00Z","year":2020,"_id":"32417996","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1007/s00345-020-03251-7","keywords":["bcg","bladder cancer","covid-19","pandemic","urology"],"topics":["Treatment"],"weight":1,"_version_":1667058206756569089,"score":52.3868}]}